Zaleplon inhalation - Alexza Pharmaceuticals

Drug Profile

Zaleplon inhalation - Alexza Pharmaceuticals

Alternative Names: AZ-007; Staccato zaleplon

Latest Information Update: 12 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alexza Pharmaceuticals
  • Class Acetamides; Hypnosedatives; Pyrimidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Insomnia

Most Recent Events

  • 09 Mar 2015 Phase-I clinical trials in Insomnia (In volunteers) in USA (Inhalation)
  • 09 Mar 2015 Alexza Pharmaceuticals plans a phase II trial for Insomnia (9175748; 254594)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top